Jefferies Financial Group’s PTC Therapeutics PTCT Stock Holding History

Jefferies Financial Group’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$111M	Buy	1,357,042 +2,583	+0.2%	+$187K	0.73%	15
2026 Q1	$92.3M	Sell	1,354,459 -304,022	-18%	-$21.5M	0.63%	18
2025 Q4	$126M	Buy	1,658,481 +73,803	+5%	+$5.36M	0.64%	22
2025 Q3	$97.3M	Buy	+1,584,678	New	+$82.5M	0.46%	27
2024 Q4	–	Sell	-522,895	Closed	-$19.4M	–	1795
2024 Q3	$19.4M	Hold	522,895	–	–	0.14%	96
2024 Q2	$16M	Buy	522,895 +250,000	+92%	+$8.1M	0.17%	98
2024 Q1	$7.94M	Sell	272,895 -4,000	-1%	-$112K	0.07%	200
2023 Q4	$7.63M	Buy	276,895 +8,760	+3%	+$200K	0.05%	286
2023 Q3	$6.01M	Buy	268,135 +240	+0.1%	+$8.93K	0.05%	292
2023 Q2	$10.9M	Buy	267,895 +252,095	+1,596%	+$12.3M	0.1%	182
2023 Q1	$765K	Buy	+15,800	New	+$722K	0.01%	979

Other funds holding PTCT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Jefferies Financial Group's PTCT Position: Q2 2026 in Review

Jefferies Financial Group increased its PTC Therapeutics (PTCT) stake by 0.19% in Q2 2026, buying an estimated $187K and bringing the position to 1,357,042 shares worth $111M. The position accounts for 0.73% of the portfolio, ranked #15.

Jefferies Financial Group first reported a position in PTCT in Q1 2023 and has held it in 11 quarters since. The position peaked at $126M in Q4 2025. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

Jefferies Financial Group held 1,357,042 shares of PTC Therapeutics worth $111M as of Q2 2026.
Jefferies Financial Group bought 2,583 PTC Therapeutics shares in Q2 2026, an estimated $187K.
PTC Therapeutics made up 0.73% of Jefferies Financial Group's portfolio in Q2 2026, its #15 holding.
Jefferies Financial Group first reported a position in PTC Therapeutics in Q1 2023 and has held it in 11 quarters since.
Jefferies Financial Group's PTC Therapeutics position peaked at $126M in Q4 2025.
382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Jefferies Financial Group's 13F filing for Q2 2026, filed 17 Aug 2026.